Grace Science

Focus: Grace Science is a pre-revenue biotechnology company focused on NGLY1-based therapies and AAV gene therapy platforms for rare genetic disorders. The company is located in Menlo Park, CA and operates at an early clinical stage with minimal public disclosure.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Grace Science

AI assessmentNot Hiring

No open roles listed right now. Follow Grace Science to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Neurodevelopmental Assessment

Genetic Syndrome

N/A

Clinical Trials (1)

NCT03834987NGLY1 Deficiency: A Prospective Natural History Study

N/A

Help build intelligence for Grace Science

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on ultra-rare disease with high unmet medical need (NGLY1 deficiency) and potential first-mover advantage in a novel therapeutic area
Cutting-edge modality focus on AAV gene therapy and protein biology offers exposure to leading-edge biotech science
Early-stage environment allows for significant career impact and direct contribution to pipeline advancement with fewer layers of bureaucracy

Watch Out For

Zero active job postings suggests minimal hiring activity or possible stage of development requiring patience before career growth opportunities emerge
Pre-revenue status with undisclosed funding presents inherent financial risk; no disclosed financials, employee count, or founding date limit transparency on company stability
Extremely early pipeline (Phase 1/2 only) with no Phase 3 or approved products means years before meaningful validation and commercial viability remain uncertain

Generated by Claude from Grace Science's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NGLY1 Natural History

NGLY1 Deficiency

N/A

Clinical Trials (1)

NCT06122766NGLY1 Natural History

N/A

GS-100

NGLY1 Deficiency

Phase 1/2

Clinical Trials (1)

NCT06199531Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency

Phase 1/2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo